Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash $ 39,100 $ 85,838
Restricted cash 24,429 0
Accounts receivable 66,692 1,500
Grant receivable 99,355 56,359
Prepaid expenses 103,460 84,629
Total current assets 333,036 228,326
Property and equipment, net 83,139 102,843
Right to use assets 300,073 384,921
Other assets:    
Patents, net 10,501 11,385
Software development costs 47,980 47,980
Deposits, long term 44,520 44,520
Total other assets 103,001 103,885
Total assets 819,249 819,975
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $951,588 and $1,014,892, respectively 3,422,187 3,188,560
Deferred revenue, short term 34,981 34,981
Lease liability, short term 130,559 119,733
Notes payable 221,480 221,480
Notes payable, related parties 685,110 790,110
Paycheck Protection Program loan, short term 0 31,580
Total current liabilities 4,494,317 4,386,444
Long term liabilities:    
Paycheck Protection Program loan, long term 0 99,860
Economic Injury Disaster loan, long term 74,188 74,300
Royalty obligation, net of discount of $5,498,564 and $5,854,226, related parties 3,223,536 2,867,874
Lease liability, long term 216,537 315,672
Deferred revenue, long term 11,137 37,301
Total liabilities 8,019,715 7,781,451
Preferred stock, no par value, 600,000 authorized    
Common stock, $0.001 par value; 750,000,000 shares authorized, 7,623,559 and 6,698,968 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively 7,623 6,699
Common stock subscribed 100,000 100,000
Additional paid in capital 65,968,641 62,994,739
Accumulated deficit (73,176,313) (69,966,692)
Total deficit attributable to BioCorRx, Inc. (7,078,433) (6,843,638)
Non-controlling interest (122,033) (117,838)
Total deficit (7,200,466) (6,961,476)
Total liabilities and deficit 819,249 819,975
Series B Convertible Preferred Stock    
Preferred stock, no par value, 600,000 authorized    
Preferred stock value 5,616 5,616
Series A Convertible Preferred Stock    
Preferred stock, no par value, 600,000 authorized    
Preferred stock value $ 16,000 $ 16,000